Rani Therapeutics Holdings, Inc. announced that it has entered into a definitive agreement with ProGen Co. Ltd. for the co-development and commercialization of RT-114, an oral RaniPill®? capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity.

Given the long half-life of PG-102, the parties intend to pursue development of RT-114 as a convenient, weekly oral dose. It also has the potential to improve body composition and nutritional health of patients owing to the unique mechanism of action of GLP-2. Additionally, ProGen's preclinical studies demonstrated that treatment with PG-102 resulted in greater glycemic control while inducing a similar degree of body weight loss versus tirzepatide and tirzepatide. ProGen recently presented results from its Phase 1 single-ascending dose study of PG-102, aGLP-1/GLP -2 dual agonist, at the 2024 American Diabetes Association conference in which PG-102 showed a favorable safety profile with lower frequencies of gastrointestinal (GI) side effects compared to competitors' trials in similar settings.

Additionally, the PK/pharmacodynamic (PD) data from this trial and preclinical studies support potential dosing of RT-114 on a weekly to monthly schedule, which could improve patient compliance.